What´s new in personalised molecular medicine and biomarkers?

In breast imaging, advances are constant. Dr Peter Brader, at the Department of Radiology, Division for Molecular and Gender Imaging, Medical University Vienna, believes a paradigm shift will take place in this and by 2025.

Diagnosis and treatment will move from a ‘one size fits all’ approach to personalised, molecular medicine with greater use of theranostics with combinations of targeted diagnostic and therapeutic agents that work sequentially or in tandem. 

‘The use of more specific molecular imaging probes, along with highthroughput serum screening and biologically-targeted biopsies, will make it possible to apply a growing array of imaging, serum and tissue biomarkers to detect and characterise breast cancer. These will include predictive biomarkers for identifying the relative sensitivity or resistance of a disease to a specific therapy, or to identify disease not in need of treatment; biomarkers for assessing treatment response earlier than is possible with conventional means; and prognostic biomarkers that provide information about the likely outcome regardless of the specific treatment applied.”

Biomarkers

These are increasingly important in the early assessment of patient response to treatment. Consultant physicist Dr Stephen Keevil, Head of Magnetic Resonance Physics and R&D Lead for Imaging at Guy’s and St Thomas’ NHS Foundation Trust as well as Reader in Medical Physics at King’s College London, said the use of functional imaging biomarkers to assess early response to ‘personalised’ treatments e.g. for cancer, has increased.

At the moment, he said, ‘the criterion is whether the tumour gets smaller on structural imaging, but this is insensitive and functional/molecular imaging will give a much earlier indication of response, which will be important as increasingly treatments will only work with specific patients, for example, for genetic reasons.’ (Dr Keevil is also 2012-13 President of the United Kingdom Radiological Congress (UKRC).
 

 

22.02.2012

Read all latest stories

Related articles

Article •

Cardiac conundrum

France – Re-opening clogged arteries with metal stents has proved a life-saver for a majority of patients with coronary disease. Yet the high rates of complications and mortality for patients with…

Photo

News • Strand-seq

AI analysis of cancer mutations: a promising step towards new therapies

Combining single-cell data with a self-learning algorithm reveals how structural changes in chromosomes can trigger cancer. This could pave the way for personalized cancer treatments.

Photo

Video • Mini-bones from the lab

Toward a personalized approach of bone cancer research and therapy

Researchers generated human mini bones in the lab which mirror the composition and function of human bone - a step toward the development of future patient-tailored models of bone cancers and tumors.

Related products

KABE Labortechnik – Consumables for blood gas analysis

Blood Gases /Electrolytes /Oximetry

KABE Labortechnik – Consumables for blood gas analysis

KABE LABORTECHNIK GmbH
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Shimadzu – MALDImini-1

Research Use Only

Shimadzu – MALDImini-1

Shimadzu Europa GmbH
Subscribe to Newsletter